6 July 2022
Advanced Medical Solutions Group plc
(“AMS” or the “Group”)
Half Year Trading Update
Winsford, UK : Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, today announces its unaudited trading update for the six months ended 30 June 2022 (the “Period”). The Group expects to announce its interim results on Wednesday 14th September 2022.
The Group is pleased to report that trading in the first half of 2022 continues to be strong and in line with the Board's expectations as healthcare markets return to normal. Group revenues for the period are expected to be approximately £58 million. Both Business Units performed well during the first half and the Board remains confident that the Group is on track to meet market expectations for the full year.
Good progress continues to be made with key regulatory and clinical programmes. In particular, the FDA 510(k) approval of LiquiBand® XL, announced in May 2022, was a significant step in the development of the LiquiBand® franchise and the product remains on track to be launched in the US during Q3 this year.
Chris Meredith, Chief Executive Officer of AMS, commented : “I am delighted with the ongoing strength in trading across the company and that we remain on track to meet expectations this year. I am also very pleased with the progress that our development teams have made. We continue to expect that a number of key projects will reach major milestones over the next 12 months and will play an important role in sustaining our top line growth in the long-term.”
– End –